Long-Term and Concentration-Dependent Beneficial Effect of Efavirenz on HDL-Cholesterol in HIV-Infected Patients

• Autor(a) principal: Pereira, SA
• Data de Publicação: 2006
• Outros Autores: Branco, T, Côrte-Real, R, Germano, I, Lampreia, F, Caixas, U, Monteiro, E
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10400.17/1777
• topic: CHLC MED; Benzoxazinas; Colesterol; Colesterol HDL; Relação Dose-Resposta a Medicamento; Estudos de Follow-Up; Glicoproteínas; Infecção por HIV; HIV-1; Oxazinas; Estudos Prospectivos; Inibidores de Transcriptase Reversa; Factores de Tempo; Resultado de Tratamento

AIMS: To investigate the long-term effects of efavirenz on cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein (LDL-C) and triglycerides (TG). METHODS: Thirty-four HIV-infected patients who commenced efavirenz therapy were monitored for 36 months. RESULTS: In patients with baseline HDL-C<40 mg.dL-1 an increase in HDL-C from 31+/-1 mg.dL-1 to 44+/-2 mg.dL-1 (95% confidence interval 5.9, 21.9, P<0.01) was observed and remained throughout the follow-up period. Median efavirenz plasma concentration was 1.98 mg.L-1 and a direct correlation between percentage of HDL-C variation or TC/HDL-C ratio and efavirenz plasma concentrations was found. CONCLUSIONS: There is evidence of a long-term and concentration-dependent beneficial effect of efavirenz on HDL-C in HIV-infected patients.